Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs 8x8 Inc (EGHT) Price & Performance

Abbott LaboratoriesTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs 8x8 Inc — how do they compare? Abbott Laboratories trades at $109.85 (market cap $187.95B), while 8x8 Inc trades at $2.16 (market cap $323.54M). The key difference: Abbott Laboratories is far larger — about 580.9× 8x8 Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.

ABTEGHT
Market Cap
$187.95B$323.54M
Sector
HealthTechnology
52-Week High
$136.62$2.76
52-Week Low
$82.57$1.59
Enterprise Value
$214.96B$590.46M
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $107.80, down slightly by 0.14% today. The stock shows a bullish technical signal with strong moving average support and a consensus analyst price target of $120.70. Recent earnings beat expectations in Q1 and Q2 2026, while revenue grew to $44.33 billion in 2025. The company secured a CE Mark for its Libre Duo glucose-ketone sensor, highlighting innovation in diabetes care.

The outlook remains positive given analyst consensus and recent product approvals, but risks include competitive pressures and macroeconomic volatility. Upside potential exists if earnings momentum continues, though valuation multiples are above industry averages, warranting caution on significant expansion.

8x8 Inc

EGHT trades at $2.30, up 1.1% today, with a bullish technical signal from moving averages. The company shows strong revenue growth, with five consecutive quarters of year-over-year increases, and has beaten EPS estimates in recent quarters. Recent news highlights the launch of a new partner program and expansion of AI capabilities across its platform. However, the stock carries a high P/E ratio of 74.67, and the company reported a net loss of $27.21 million for 2025.

The outlook is cautiously optimistic, with analyst consensus pointing to significant upside with a $3.13 price target. Key opportunities include sustained revenue growth and AI-driven product expansion, while risks involve high valuation, debt levels, and the challenge of achieving consistent profitability. Institutional sentiment is mixed but leans positive.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About 8x8 Inc

8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.

Read more on EGHT